Intellia Therapeutics, Inc. Investors: Please contact the Portnoy Law Firm to recover your losses. April 14, 2025 Deadline to file Lead Plaintiff Motion.

Core Viewpoint - Intellia Therapeutics, Inc. is facing a class action lawsuit due to alleged misleading statements regarding the viability and development of its gene editing therapy NTLA-3001, leading to significant stock price declines [4][5]. Company Overview - Intellia Therapeutics is a genome editing company focused on developing curative therapeutics [3]. Class Action Details - The class action lawsuit represents investors who purchased Intellia securities between July 30, 2024, and January 8, 2025, with a deadline for filing a lead plaintiff motion set for April 14, 2025 [1]. - The lawsuit alleges that Intellia's management made false statements about the reliability of NTLA-3001's development and failed to disclose critical information about the program's viability [4]. Allegations Against Intellia - The lawsuit claims that Intellia misrepresented the timelines and feasibility of NTLA-3001, asserting that the viral-based editing methods were costly and inefficient compared to non-viral alternatives [4]. - It is alleged that Intellia was not prepared to dose patients with NTLA-3001 or maintain its research and development efforts effectively [4]. - Following a company reorganization announcement on January 9, 2025, which included the discontinuation of NTLA-3001, Intellia's stock price dropped by over 15% [5].